EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

Leena Karimi, Carla L Alves, Mikkel G Terp, Martina Tuttolomondo, Neil Portman, Sidse Ehmsen, Lene E Johansen, Martin Bak, Elgene Lim, Henrik J Ditzel iD

Cancer Communications · 2023

DOI: 10.1002/cac2.12425 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Cancer Communications, 2023. Verfasst von Leena Karimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleFulvestrantPhosphatidylinositol 3-KinasesCell Line, TumorSignal TransductionCyclin-Dependent Kinase 4

Substanzen

FulvestrantPhosphatidylinositol 3-KinasesCDK4 protein, humanCyclin-Dependent Kinase 4

Autor:innen und Institutionen

  • Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
  • St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia.
  • Department of Oncology, Institute of Clinical Research, Odense University Hospital, Odense, Denmark.
  • Department of Pathology, Sydvestjysk Sygehus, Esbjerg, Denmark.
  • Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.

ORCID-Profile: Henrik J Ditzel

Zitieren

APA

Karimi, L., Alves, C. L., Terp, M. G., Tuttolomondo, M., Portman, N., Ehmsen, S., Johansen, L. E., Bak, M., Lim, E., & Ditzel, H. J. (2023). Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor. Cancer Communications. https://doi.org/10.1002/cac2.12425

Vancouver

Karimi L, Alves CL, Terp MG, Tuttolomondo M, Portman N, Ehmsen S, et al. Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor. Cancer Communications. 2023. doi:10.1002/cac2.12425

BibTeX
@article{Karimi2023,
  author = {Karimi, Leena and Alves, Carla L and Terp, Mikkel G and Tuttolomondo, Martina and Portman, Neil and Ehmsen, Sidse and Johansen, Lene E and Bak, Martin and Lim, Elgene and Ditzel, Henrik J},
  title = {Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor},
  journal = {Cancer Communications},
  year = {2023},
  doi = {10.1002/cac2.12425}
}
Kostenlos starten →